%PDF-1.6
%
1 0 obj
<>
endobj
2 0 obj
<>stream
Mattias Neyt, Joan Vlayen, Stephan Devriese, Cécile Camberlin
First- and second-line bevacizumab in ovarian cancer: A Belgian cost-utility analysis
www.plosone.org
www.plosone.org
endstream
endobj
3 0 obj
<>/XObject<>>>/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 9 0 R/Annots 10 0 R/Contents 11 0 R/TrimBox[0 0 612 792]>>
endobj
10 0 obj
[12 0 R 13 0 R 14 0 R 15 0 R 16 0 R 17 0 R 18 0 R 19 0 R 20 0 R 21 0 R 22 0 R 23 0 R]
endobj
12 0 obj
<>/Border[0 0 0]/Dest(Rpone.0195134.ref001)>>
endobj
13 0 obj
<>/Border[0 0 0]/Dest(Rpone.0195134.ref002)>>
endobj
14 0 obj
<>/Border[0 0 0]/Dest(Rpone.0195134.ref003)>>
endobj
15 0 obj
<>/Border[0 0 0]/Dest(Rpone.0195134.ref004)>>
endobj
16 0 obj
<>/Border[0 0 0]/Dest(Rpone.0195134.ref004)>>
endobj
17 0 obj
<>/Border[0 0 0]/Dest(Rpone.0195134.ref005)>>
endobj
18 0 obj
<>/Border[0 0 0]/Dest(Rpone.0195134.ref007)>>
endobj
19 0 obj
<>/Border[0 0 0]/Dest(Rpone.0195134.ref004)>>
endobj
20 0 obj
<>/Border[0 0 0]/Dest(Rpone.0195134.ref008)>>
endobj
21 0 obj
<>/Border[0 0 0]/Dest(Rpone.0195134.ref009)>>
endobj
22 0 obj
<>/Border[0 0 0]/Dest(Rpone.0195134.ref009)>>
endobj
23 0 obj
<>/Border[0 0 0]/A 24 0 R>>
endobj
24 0 obj
<>
endobj
11 0 obj
[25 0 R 26 0 R 27 0 R 28 0 R 29 0 R 30 0 R 31 0 R 32 0 R 33 0 R 34 0 R]
endobj
25 0 obj
<>stream
q
0.45 0.36 0.35 0.01 k
0 w
575.9997 666.2299 m
199.9998 666.2299 l
199.9998 666.7299 l
575.9997 666.7299 l
f*
0.83 0.64 0.02 0 k
299.622 588.926 m
304.3843 588.926 l
h
f*
437.3858 549.9213 m
442.148 549.9213 l
h
f*
371.2819 536.9386 m
376.0441 536.9386 l
h
f*
303.0236 510.9165 m
307.7858 510.9165 l
h
f*
229.4362 497.9339 m
234.1984 497.9339 l
h
f*
442.715 432.9071 m
447.4772 432.9071 l
h
f*
452.6362 432.9071 m
457.3984 432.9071 l
h
f*
504.6803 380.9197 m
509.4425 380.9197 l
h
f*
388.3465 159.9307 m
393.222 159.9307 l
h
f*
465.9591 120.926 m
470.8346 120.926 l
h
f*
321.789 81.9213 m
326.6646 81.9213 l
h
f*
0 g
1 j
1 J
9.5 0 0 9.5 200.0125 707.7543 cm
BT
/F0 1 Tf
1 TL
0.0053 Tc
0 0 Td
(Price)Tj
2.5183 0 Td
(reductions)Tj
4.8756 0 Td
(have)Tj
2.399 0 Td
(a)Tj
0.7758 0 Td
(major)Tj
2.7451 0 Td
(impact)Tj
3.1927 0 Td
(on)Tj
1.3367 0 Td
(the)Tj
1.6232 0 Td
(estimated)Tj
4.5951 0 Td
(ICERs.)Tj
3.4195 0 Td
(It)Tj
0.7997 0 Td
(is)Tj
0.9488 0 Td
(recommended)Tj
6.648 0 Td
(to)Tj
1.0682 0 Td
(take)Tj
-36.9457 -1.474 Td
(these)Tj
2.6854 0 Td
(findings)Tj
3.694 0 Td
(into)Tj
1.8499 0 Td
(account)Tj
3.7477 0 Td
(when)Tj
2.6198 0 Td
(re-evaluating)Tj
6.0512 0 Td
(the)Tj
1.6232 0 Td
(reimbursement)Tj
6.9404 0 Td
(of)Tj
1.0682 0 Td
(bevacizumab)Tj
6.1527 0 Td
(in)Tj
-36.4325 -1.474 Td
(ovarian)Tj
3.5209 0 Td
(cancer.)Tj
ET
Q
q
1 j
1 J
0 w
11.9999 0 0 11.9999 200.0125 619.9937 cm
BT
/F2 1 Tf
1 TL
-0.0033 Tc
0 0 Td
(Introduction)Tj
ET
Q
q
1 j
1 J
0 w
10 0 0 10 200.0125 602.9858 cm
BT
/F6 1 Tf
1 TL
-0.004 Tc
0 0 Td
(In)Tj
1.1055 0 Td
(Belgium,)Tj
3.7757 0 Td
(ovarian)Tj
3.2371 0 Td
(cancer)Tj
2.846 0 Td
(is)Tj
0.8447 0 Td
(the)Tj
1.474 0 Td
(eighth)Tj
2.7269 0 Td
(most)Tj
2.2054 0 Td
(frequent)Tj
3.6113 0 Td
(female)Tj
2.8516 0 Td
(cancer)Tj
2.846 0 Td
(and)Tj
1.7291 0 Td
(the)Tj
1.4683 0 Td
(fifth)Tj
1.8879 0 Td
(in)Tj
1.0375 0 Td
(terms)Tj
2.4945 0 Td
(of)Tj
-36.1415 -1.2982 Td
(female)Tj
2.8516 0 Td
(cancer)Tj
2.846 0 Td
(mortality.[)Tj
0.83 0.64 0.02 0 k
(1)Tj
0 g
(])Tj
5.3007 0 Td
(In)Tj
1.1055 0 Td
(2014,)Tj
2.3471 0 Td
(848)Tj
1.6497 0 Td
(women)Tj
3.2032 0 Td
(were)Tj
2.1203 0 Td
(diagnosed)Tj
4.2803 0 Td
(with)Tj
2.0012 0 Td
(ovarian)Tj
3.2315 0 Td
(cancer.)Tj
3.0727 0 Td
(The)Tj
-34.0098 -1.2983 Td
(mean)Tj
2.4434 0 Td
(age)Tj
1.542 0 Td
(at)Tj
0.9525 0 Td
(diagnosis)Tj
3.9571 0 Td
(was)Tj
1.7008 0 Td
(66.7)Tj
1.8708 0 Td
(years.)Tj
2.4945 0 Td
(Around)Tj
3.3846 0 Td
(72%)Tj
1.9275 0 Td
(of)Tj
1.0148 0 Td
(all)Tj
1.1452 0 Td
(ovarian)Tj
3.2371 0 Td
(cancers)Tj
3.2088 0 Td
(are)Tj
1.4457 0 Td
(diagnosed)Tj
4.2803 0 Td
(in)Tj
1.0375 0 Td
(an)Tj
-35.6426 -1.3039 Td
(advanced)Tj
3.9911 0 Td
(stage)Tj
2.2053 0 Td
(when)Tj
2.4038 0 Td
(the)Tj
1.4683 0 Td
(tumour)Tj
3.2712 0 Td
(has)Tj
1.542 0 Td
(already)Tj
3.1125 0 Td
(spread)Tj
2.8516 0 Td
(outside)Tj
3.1351 0 Td
(the)Tj
1.4683 0 Td
(pelvic)Tj
2.5512 0 Td
(area,)Tj
2.109 0 Td
(to)Tj
1.0261 0 Td
(the)Tj
1.4683 0 Td
(retroperito-)Tj
-32.6038 -1.2983 Td
(neal)Tj
1.8651 0 Td
(lymph)Tj
2.7836 0 Td
(nodes)Tj
2.5796 0 Td
(or)Tj
1.0941 0 Td
(beyond)Tj
3.1861 0 Td
(the)Tj
1.4627 0 Td
(peritoneum)Tj
4.9209 0 Td
(\(stage)Tj
2.5342 0 Td
(III-IV\).[)Tj
0.83 0.64 0.02 0 k
(2)Tj
0 g
(])Tj
4.3426 0 Td
(The)Tj
1.7802 0 Td
(global)Tj
2.6192 0 Td
(relative)Tj
3.1351 0 Td
(five-year)Tj
3.6793 0 Td
(sur-)Tj
-35.9827 -1.2982 Td
(vival)Tj
2.0749 0 Td
(is)Tj
0.8504 0 Td
(42.6%,)Tj
2.8516 0 Td
(but)Tj
1.5534 0 Td
(only)Tj
1.9786 0 Td
(23.8%)Tj
2.6305 0 Td
(for)Tj
1.3833 0 Td
(stage)Tj
2.1997 0 Td
(IV.[)Tj
0.83 0.64 0.02 0 k
(3)Tj
0 g
(])Tj
-14.3262 -1.3039 Td
(In)Tj
1.1111 0 Td
(advanced)Tj
3.9912 0 Td
(stage,)Tj
2.4321 0 Td
(cytoreductive)Tj
5.6182 0 Td
(surgery)Tj
3.1975 0 Td
(and)Tj
1.7291 0 Td
(chemotherapy)Tj
5.9471 0 Td
(are)Tj
1.4513 0 Td
(recommended)Tj
6.0321 0 Td
(according)Tj
-32.7059 -1.2983 Td
(to)Tj
1.0261 0 Td
(the)Tj
1.4683 0 Td
(Belgian)Tj
3.1861 0 Td
(guidelines.[)Tj
0.83 0.64 0.02 0 k
(4)Tj
0 g
(])Tj
5.658 0 Td
(Standard)Tj
3.838 0 Td
(first-line)Tj
3.6397 0 Td
(chemotherapy)Tj
5.9471 0 Td
(combination)Tj
5.3461 0 Td
(is)Tj
0.8504 0 Td
(carboplatin-pac-)Tj
-30.9598 -1.2983 Td
(litaxel.[)Tj
0.83 0.64 0.02 0 k
(4)Tj
0 g
(])Tj
3.9798 0 Td
(For)Tj
1.627 0 Td
(second-line)Tj
4.8473 0 Td
(chemotherapy,)Tj
6.1738 0 Td
(this)Tj
1.6724 0 Td
(combination)Tj
5.3461 0 Td
(may)Tj
1.9332 0 Td
(be)Tj
1.1452 0 Td
(re-used)Tj
3.2088 0 Td
(in)Tj
1.0375 0 Td
(platinum-sensi-)Tj
-30.9711 -1.3039 Td
(tive)Tj
1.661 0 Td
(patients,)Tj
3.5943 0 Td
(and)Tj
1.7292 0 Td
(carboplatin)Tj
4.7735 0 Td
(may)Tj
1.9332 0 Td
(also)Tj
1.7631 0 Td
(be)Tj
1.1509 0 Td
(switched)Tj
3.736 0 Td
(to)Tj
1.0262 0 Td
(cisplatin.)Tj
3.804 0 Td
(In)Tj
1.1112 0 Td
(case)Tj
1.8595 0 Td
(of)Tj
1.0148 0 Td
(allergy)Tj
2.863 0 Td
(to)Tj
1.0261 0 Td
(platinum-)Tj
-33.046 -1.2983 Td
(based)Tj
2.4717 0 Td
(compounds,)Tj
5.1874 0 Td
(or)Tj
1.0942 0 Td
(non-response)Tj
5.6862 0 Td
(of)Tj
1.0148 0 Td
(the)Tj
1.474 0 Td
(tumour)Tj
3.2712 0 Td
(to)Tj
1.0261 0 Td
(platinum-based)Tj
6.48 0 Td
(chemotherapy)Tj
5.9471 0 Td
(\(plati-)Tj
-33.6527 -1.2982 Td
(num-refractory)Tj
6.4062 0 Td
(tumour\))Tj
3.6113 0 Td
(or)Tj
1.0999 0 Td
(in)Tj
1.0374 0 Td
(case)Tj
1.8595 0 Td
(of)Tj
1.0148 0 Td
(relapse)Tj
2.9991 0 Td
(within)Tj
2.8119 0 Td
(6)Tj
0.6974 0 Td
(months)Tj
3.2825 0 Td
(after)Tj
2.0352 0 Td
(this)Tj
1.6724 0 Td
(kind)Tj
2.058 0 Td
(of)Tj
1.0148 0 Td
(chemotherapy)Tj
-31.6004 -1.2983 Td
(\(platinum-resistant)Tj
7.9312 0 Td
(tumour\),)Tj
3.8381 0 Td
(paclitaxel)Tj
3.9742 0 Td
(alone,)Tj
2.6022 0 Td
(pegylated)Tj
4.0138 0 Td
(liposomal)Tj
4.1272 0 Td
(doxorubicin)Tj
5.1364 0 Td
(hydrochloride)Tj
-31.6231 -1.3039 Td
(\(PLD\),)Tj
2.9593 0 Td
(topotecan)Tj
4.1782 0 Td
(or)Tj
1.0942 0 Td
(gemcitabine)Tj
5.0967 0 Td
(represent)Tj
3.9628 0 Td
(possible)Tj
3.4072 0 Td
(options.[)Tj
0.83 0.64 0.02 0 k
(5)Tj
0 g
()Tj
0.83 0.64 0.02 0 k
(7)Tj
0 g
(])Tj
-19.5022 -1.2983 Td
(For)Tj
1.627 0 Td
(epithelial)Tj
3.8721 0 Td
(ovarian,)Tj
3.464 0 Td
(fallopian)Tj
3.7076 0 Td
(or)Tj
1.0999 0 Td
(primitive)Tj
3.9061 0 Td
(peritoneal)Tj
4.2519 0 Td
(cancer,)Tj
3.0728 0 Td
(front-line)Tj
4.0705 0 Td
(treatment)Tj
4.1329 0 Td
(with)Tj
-34.401 -1.2982 Td
(bevacizumab)Tj
5.4311 0 Td
(in)Tj
1.0318 0 Td
(stage)Tj
2.2053 0 Td
(IIIB-IIIC-IV)Tj
5.2384 0 Td
(was)Tj
1.7008 0 Td
(authorized)Tj
4.5127 0 Td
(by)Tj
1.1849 0 Td
(the)Tj
1.4683 0 Td
(European)Tj
4.1216 0 Td
(Medicines)Tj
4.354 0 Td
(Agency)Tj
3.2201 0 Td
(on)Tj
1.2756 0 Td
(21)Tj
-35.7446 -1.3039 Td
(September)Tj
4.4787 0 Td
(2011.)Tj
2.347 0 Td
(This)Tj
1.9899 0 Td
(indication)Tj
4.3087 0 Td
(was)Tj
1.6951 0 Td
(extended)Tj
3.8607 0 Td
(to)Tj
1.0262 0 Td
(recurrent)Tj
3.9798 0 Td
(platinum-sensitive)Tj
7.6308 0 Td
(cancer)Tj
2.846 0 Td
(on)Tj
1.2756 0 Td
(20)Tj
-35.4385 -1.2983 Td
(September)Tj
4.4787 0 Td
(2012)Tj
2.1203 0 Td
(and)Tj
1.7348 0 Td
(to)Tj
1.0204 0 Td
(recurrent)Tj
3.9798 0 Td
(platinum-resistant)Tj
7.5968 0 Td
(cancer)Tj
2.8403 0 Td
(on)Tj
1.2756 0 Td
(31)Tj
1.1736 0 Td
(July)Tj
1.7801 0 Td
(2014.[)Tj
0.83 0.64 0.02 0 k
(4)Tj
0 g
(])Tj
3.5036 0 Td
(In)Tj
1.1055 0 Td
(Belgium,)Tj
-32.6095 -1.2983 Td
(reimbursement)Tj
6.3835 0 Td
(for)Tj
1.3833 0 Td
(epithelial)Tj
3.8721 0 Td
(ovarian,)Tj
3.4639 0 Td
(fallopian)Tj
3.7077 0 Td
(or)Tj
1.0942 0 Td
(primitive)Tj
3.9061 0 Td
(peritoneal)Tj
4.2576 0 Td
(cancer)Tj
2.846 0 Td
(\(onwards)Tj
3.9912 0 Td
(we)Tj
-34.9056 -1.3039 Td
(refer)Tj
2.0976 0 Td
(to)Tj
1.0261 0 Td
(this)Tj
1.6724 0 Td
(by)Tj
1.1792 0 Td
(using)Tj
2.3925 0 Td
(the)Tj
1.4683 0 Td
(term)Tj
2.1316 0 Td
(`ovarian)Tj
3.464 0 Td
(cancer'\))Tj
3.4015 0 Td
(can)Tj
1.6214 0 Td
(be)Tj
1.1509 0 Td
(allowed)Tj
3.2882 0 Td
(in)Tj
1.0374 0 Td
(three)Tj
2.2677 0 Td
(types)Tj
2.2734 0 Td
(of)Tj
1.0148 0 Td
(indications:)Tj
4.8926 0 Td
(\(1\))Tj
-36.3796 -1.2983 Td
(first-line)Tj
3.6396 0 Td
(treatment)Tj
4.1386 0 Td
(of)Tj
1.0148 0 Td
(stage)Tj
2.1996 0 Td
(FIGO)Tj
2.5512 0 Td
(IV)Tj
1.2529 0 Td
(ovarian)Tj
3.2372 0 Td
(cancer)Tj
2.8459 0 Td
(\(in)Tj
1.372 0 Td
(combination)Tj
5.3518 0 Td
(with)Tj
1.9955 0 Td
(carboplatin)Tj
4.7735 0 Td
(and)Tj
-34.3726 -1.2982 Td
(paclitaxel)Tj
3.9741 0 Td
(for)Tj
1.3833 0 Td
(a)Tj
0.6576 0 Td
(maximum)Tj
4.371 0 Td
(of)Tj
1.0148 0 Td
(6)Tj
0.6973 0 Td
(treatment)Tj
4.1329 0 Td
(cycles)Tj
2.5569 0 Td
(and)Tj
1.7291 0 Td
(then)Tj
2.0182 0 Td
(in)Tj
1.0318 0 Td
(monotherapy)Tj
5.6296 0 Td
(until)Tj
2.109 0 Td
(either)Tj
2.5341 0 Td
(a)Tj
0.652 0 Td
(maxi-)Tj
-34.4917 -1.2983 Td
(mum)Tj
2.3867 0 Td
(of)Tj
1.0148 0 Td
(15)Tj
1.1679 0 Td
(months)Tj
3.2825 0 Td
(in)Tj
1.0374 0 Td
(total,)Tj
2.2281 0 Td
(disease)Tj
3.0217 0 Td
(progression)Tj
4.9152 0 Td
(or)Tj
1.0999 0 Td
(unacceptable)Tj
5.4254 0 Td
(toxicity\);)Tj
3.7701 0 Td
(\(2\))Tj
1.3719 0 Td
(first)Tj
1.8085 0 Td
(recurrence)Tj
-32.5301 -1.3039 Td
(of)Tj
1.0147 0 Td
(ovarian)Tj
3.2372 0 Td
(cancer)Tj
2.8403 0 Td
(in)Tj
1.0375 0 Td
(patients)Tj
3.3675 0 Td
(sensitive)Tj
3.6283 0 Td
(to)Tj
1.0205 0 Td
(platin)Tj
2.5341 0 Td
(salts)Tj
1.9219 0 Td
(who)Tj
1.9389 0 Td
(have)Tj
2.058 0 Td
(not)Tj
1.576 0 Td
(yet)Tj
1.3946 0 Td
(been)Tj
2.1203 0 Td
(treated)Tj
2.9991 0 Td
(with)Tj
1.9956 0 Td
(bevaci-)Tj
-34.6845 -1.2983 Td
(zumab)Tj
2.9139 0 Td
(or)Tj
1.0942 0 Td
(other)Tj
2.3414 0 Td
(VEGF)Tj
2.7269 0 Td
(inhibitors)Tj
4.1329 0 Td
(or)Tj
1.0942 0 Td
(other)Tj
2.3471 0 Td
(agents)Tj
2.7439 0 Td
(aiming)Tj
3.016 0 Td
(at)Tj
0.9468 0 Td
(the)Tj
1.4627 0 Td
(VEGF)Tj
2.7269 0 Td
(receptor)Tj
3.5489 0 Td
(\(in)Tj
1.372 0 Td
(combination)Tj
-32.4678 -1.2982 Td
(with)Tj
1.9955 0 Td
(carboplatin)Tj
4.7735 0 Td
(and)Tj
1.7292 0 Td
(gemcitabine)Tj
5.1023 0 Td
(during)Tj
2.9253 0 Td
(6)Tj
0.6973 0 Td
(to)Tj
1.0205 0 Td
(maximum)Tj
4.3767 0 Td
(10)Tj
1.1678 0 Td
(cycles)Tj
2.5569 0 Td
(and)Tj
1.7291 0 Td
(then)Tj
2.0183 0 Td
(in)Tj
1.0374 0 Td
(monotherapy)Tj
-31.1298 -1.304 Td
(until)Tj
2.1089 0 Td
(disease)Tj
3.0161 0 Td
(progression\);)Tj
5.4821 0 Td
(or)Tj
1.0999 0 Td
(\(3\))Tj
1.3776 0 Td
(second-line)Tj
4.8472 0 Td
(treatment)Tj
4.1329 0 Td
(of)Tj
1.0148 0 Td
(ovarian)Tj
3.2371 0 Td
(cancer)Tj
2.846 0 Td
(in)Tj
1.0375 0 Td
(patients)Tj
3.3675 0 Td
(resistant)Tj
-33.5676 -1.2982 Td
(to)Tj
1.0261 0 Td
(platin)Tj
2.5285 0 Td
(salts)Tj
1.9219 0 Td
(who)Tj
1.9388 0 Td
(have)Tj
2.058 0 Td
(not)Tj
1.576 0 Td
(received)Tj
3.532 0 Td
(more)Tj
2.3414 0 Td
(than)Tj
2.0296 0 Td
(2)Tj
0.6973 0 Td
(chemotherapy)Tj
5.947 0 Td
(lines)Tj
2.0693 0 Td
(and)Tj
1.7291 0 Td
(have)Tj
2.058 0 Td
(not)Tj
1.576 0 Td
(been)Tj
-33.029 -1.2983 Td
(treated)Tj
2.9933 0 Td
(with)Tj
1.9956 0 Td
(bevacizumab)Tj
5.4311 0 Td
(or)Tj
1.0942 0 Td
(other)Tj
2.3471 0 Td
(VEGF)Tj
2.7269 0 Td
(inhibitors)Tj
4.1385 0 Td
(or)Tj
1.0999 0 Td
(other)Tj
2.3471 0 Td
(agents)Tj
2.7495 0 Td
(aiming)Tj
3.0161 0 Td
(at)Tj
0.9524 0 Td
(the)Tj
1.4684 0 Td
(VEGF)Tj
2.7269 0 Td
(recep-)Tj
-35.087 -1.3039 Td
(tor)Tj
1.3946 0 Td
(\(in)Tj
1.3776 0 Td
(combination)Tj
5.3461 0 Td
(with)Tj
1.9956 0 Td
(paclitaxel,)Tj
4.2009 0 Td
(topotecan)Tj
4.1783 0 Td
(or)Tj
1.0998 0 Td
(pegylated)Tj
4.0082 0 Td
(liposomal)Tj
4.1272 0 Td
(doxorubicin)Tj
5.1363 0 Td
(until)Tj
2.109 0 Td
(dis-)Tj
-34.9736 -1.2983 Td
(ease)Tj
1.8595 0 Td
(progression)Tj
4.9209 0 Td
(or)Tj
1.0998 0 Td
(unacceptable)Tj
5.4255 0 Td
(toxicity\).)Tj
0.005 Tc
-12.1095 -1.2982 Td
(The)Tj
1.8141 0 Td
(reimbursement)Tj
6.497 0 Td
(terms)Tj
2.5398 0 Td
(were)Tj
2.16 0 Td
(negotiated)Tj
4.5014 0 Td
(based)Tj
2.5171 0 Td
(on)Tj
1.2926 0 Td
(a)Tj
0.6633 0 Td
(contract)Tj
3.5943 0 Td
(\(managed)Tj
4.286 0 Td
(entry)Tj
2.3641 0 Td
(agree-)Tj
-33.4259 -1.3039 Td
(ment\))Tj
2.6928 0 Td
(between)Tj
3.5944 0 Td
(the)Tj
1.4966 0 Td
(Minister)Tj
3.7191 0 Td
(of)Tj
1.0318 0 Td
(Social)Tj
2.6305 0 Td
(Affairs)Tj
2.9764 0 Td
(and)Tj
1.7574 0 Td
(Public)Tj
2.8006 0 Td
(Health)Tj
2.9707 0 Td
(and)Tj
1.7575 0 Td
(the)Tj
1.4967 0 Td
(manufacturer)Tj
5.7996 0 Td
(after)Tj
-34.7241 -1.2983 Td
(the)Tj
1.4966 0 Td
(regular)Tj
3.1181 0 Td
(procedure)Tj
4.3994 0 Td
(did)Tj
1.5647 0 Td
(not)Tj
1.6044 0 Td
(result)Tj
2.5001 0 Td
(in)Tj
1.0545 0 Td
(the)Tj
1.4967 0 Td
(drug)Tj
2.1486 0 Td
(entry)Tj
2.3584 0 Td
(in)Tj
1.0545 0 Td
(the)Tj
1.4967 0 Td
(reimbursement)Tj
6.5026 0 Td
(schedule)Tj
3.7474 0 Td
(\(article)Tj
-34.5427 -1.2983 Td
(81)Tj
1.1905 0 Td
(of)Tj
1.0318 0 Td
(the)Tj
1.4967 0 Td
(Royal)Tj
2.5285 0 Td
(Decree)Tj
3.0727 0 Td
(of)Tj
1.0318 0 Td
(21)Tj
1.1906 0 Td
(December)Tj
4.422 0 Td
(2001\).[)Tj
0.83 0.64 0.02 0 k
(8)Tj
0 g
(])Tj
3.9231 0 Td
(In)Tj
1.1282 0 Td
(theory,)Tj
3.0897 0 Td
(both)Tj
2.0976 0 Td
(financial-based)Tj
6.412 0 Td
(agreements,)Tj
-32.6152 -1.2982 Td
(performance-linked)Tj
8.3678 0 Td
(coverage)Tj
3.7927 0 Td
(and)Tj
1.7575 0 Td
(coverage)Tj
3.7984 0 Td
(with)Tj
2.0296 0 Td
(evidence)Tj
3.787 0 Td
(development)Tj
5.5049 0 Td
(agreements)Tj
4.8812 0 Td
(are)Tj
1.474 0 Td
(pos-)Tj
-35.3931 -1.304 Td
(sible.)Tj
2.3017 0 Td
(Unfortunately,)Tj
6.2532 0 Td
(the)Tj
1.4966 0 Td
(appendices)Tj
4.7565 0 Td
(of)Tj
1.0319 0 Td
(such)Tj
2.0976 0 Td
(a)Tj
0.6576 0 Td
(contract,)Tj
3.8324 0 Td
(including)Tj
4.1216 0 Td
(e.g.)Tj
1.5987 0 Td
(a)Tj
0.6633 0 Td
(possible)Tj
3.4809 0 Td
(request)Tj
3.1918 0 Td
(for)Tj
-35.4838 -1.2982 Td
(further)Tj
3.0897 0 Td
(evidence)Tj
3.7814 0 Td
(or)Tj
1.1168 0 Td
(results)Tj
2.8743 0 Td
(of)Tj
1.0318 0 Td
(price)Tj
2.2678 0 Td
(negotiations,)Tj
5.4878 0 Td
(are)Tj
1.474 0 Td
(confidential.[)Tj
0.83 0.64 0.02 0 k
(9)Tj
0 g
(])Tj
6.5253 0 Td
(However,)Tj
4.1499 0 Td
(research)Tj
3.6283 0 Td
(eval-)Tj
-35.4271 -1.2983 Td
(uating)Tj
2.8119 0 Td
(the)Tj
1.4967 0 Td
(first)Tj
1.8538 0 Td
(71)Tj
1.1849 0 Td
(approved)Tj
4.0479 0 Td
(contracts)Tj
3.9684 0 Td
(in)Tj
1.0488 0 Td
(Belgium)Tj
3.617 0 Td
(found)Tj
2.6589 0 Td
(that)Tj
1.8142 0 Td
(the)Tj
1.4967 0 Td
(compensation)Tj
5.9867 0 Td
(mechanisms)Tj
-31.9859 -1.3039 Td
(used)Tj
2.0919 0 Td
(in)Tj
1.0545 0 Td
(Belgium)Tj
3.6113 0 Td
(mainly)Tj
3.0444 0 Td
(exist)Tj
2.0806 0 Td
(out)Tj
1.5817 0 Td
(of)Tj
1.0318 0 Td
(a)Tj
0.6633 0 Td
(percentage)Tj
4.6375 0 Td
(of)Tj
1.0375 0 Td
(the)Tj
1.491 0 Td
(declared)Tj
3.6737 0 Td
(turnover)Tj
3.7927 0 Td
(\(84.6%\))Tj
3.3732 0 Td
(or)Tj
1.1168 0 Td
(a)Tj
0.6633 0 Td
(fixed)Tj
-34.9452 -1.2983 Td
(amount)Tj
3.4072 0 Td
(per)Tj
1.559 0 Td
(package)Tj
3.4753 0 Td
(\(10.8%\).[)Tj
0.83 0.64 0.02 0 k
(9)Tj
0 g
(])Tj
4.7905 0 Td
(On)Tj
1.5364 0 Td
(1)Tj
0.7029 0 Td
(March)Tj
2.914 0 Td
(2014,)Tj
2.3925 0 Td
(a)Tj
0.6633 0 Td
(first)Tj
1.8482 0 Td
(3-year)Tj
2.7836 0 Td
(contract)Tj
3.5999 0 Td
(was)Tj
1.7235 0 Td
(concluded)Tj
4.456 0 Td
(for)Tj
ET
Q
q
1 j
1 J
0 w
576 737.1 m
36 737.1 l
36 737.6 l
576 737.6 l
f*
36 741.2598 107.1496 23.6976 re
W* n
q
107.0929 0 0 23.6409 36 741.3165 cm
q
/I0 Do
Q
Q
Q
q
0 0 612 792 re
W* n
1 j
1 J
0 w
7.9999 0 0 7.9999 461.1401 745.7952 cm
BT
/F0 1 Tf
1 TL
-0.005 Tc
0 0 Td
(Cost-ut)Tj
3.1677 0 Td
(ility)Tj
1.6299 0 Td
(analysis)Tj
3.763 0 Td
(bevacizum)Tj
4.6985 0 Td
(ab)Tj
ET
Q
q
1 j
1 J
0 w
36 48.0002 m
576 48.0002 l
576 47.5002 l
36 47.5002 l
f*
0.83 0.64 0.02 0 k
81.5811 34.9228 m
237.8835 34.9228 l
h
f*
0 g
7.9999 0 0 7.9999 36 36 cm
BT
/F0 1 Tf
1 TL
-0.005 Tc
0 0 Td
(PLOS)Tj
2.8559 0 Td
(ONE)Tj
2.3669 0 Td
(|)Tj
0.83 0.64 0.02 0 k
0.4748 0 Td
(https://doi.or)Tj
5.4142 0 Td
(g/10.137)Tj
3.8198 0 Td
(1/journal.po)Tj
5.1236 0 Td
(ne.01951)Tj
4.089 0 Td
(34)Tj
0 g
2.0906 0 Td
(April)Tj
2.1827 0 Td
(9,)Tj
1.0417 0 Td
(2018)Tj
35.6814 0 Td
(2)Tj
0.7654 0 Td
(/)Tj
ET
endstream
endobj
26 0 obj
<>stream
endstream
endobj
27 0 obj
<>stream
endstream
endobj
28 0 obj
<>stream
endstream
endobj
29 0 obj
<>stream
endstream
endobj
30 0 obj
<>stream
endstream
endobj
31 0 obj
<>stream
endstream
endobj
32 0 obj
<>stream
endstream
endobj
33 0 obj
<>stream
endstream
endobj
34 0 obj
<>stream
BT
66.402 0 Td
(16)Tj
ET
Q
endstream
endobj
35 0 obj
<>/ColorSpace<>/XObject<>>>/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 9 0 R/Annots 41 0 R/Contents 42 0 R/TrimBox[0 0 612 792]>>
endobj
39 0 obj
<>
endobj
43 0 obj
<>
endobj
44 0 obj
<>stream
%!PS-AdobeFont-1.0
11 dict begin
/FontName /TeX_CM_Maths_Italic def
/FontType 1 def
/FontBBox {-31 -239 1041 750} readonly def
/FontMatrix [0.001 0 0 0.001 0 0] readonly def
/PaintType 0 def
/FontInfo 8 dict dup begin
/FullName (TeX_CM_Maths_Italic) readonly def
/BaseFontName (TeX_CM_Maths_Italic) def
end def
/Encoding 256 array
0 1 255 {1 index exch /.notdef put} for
dup 0 /C0 put
dup 1 /C1 put
dup 2 /C2 put
dup 3 /C3 put
dup 4 /C4 put
dup 5 /C5 put
dup 6 /C6 put
dup 7 /C7 put
dup 8 /C8 put
dup 9 /C9 put
dup 10 /C10 put
dup 11 /C11 put
dup 12 /C12 put
dup 13 /C13 put
dup 14 /C14 put
dup 15 /C15 put
dup 16 /C16 put
dup 17 /C17 put
dup 18 /C18 put
dup 19 /C19 put
dup 20 /C20 put
dup 21 /C21 put
dup 22 /C22 put
dup 23 /C23 put
dup 24 /C24 put
dup 25 /C25 put
dup 26 /C26 put
dup 27 /C27 put
dup 28 /C28 put
dup 29 /C29 put
dup 30 /C30 put
dup 31 /C31 put
dup 32 /space put
dup 33 /exclam put
dup 34 /quotedbl put
dup 35 /numbersign put
dup 36 /dollar put
dup 37 /percent put
dup 38 /ampersand put
dup 39 /quoteright put
dup 40 /parenleft put
dup 41 /parenright put
dup 42 /asterisk put
dup 43 /plus put
dup 44 /comma put
dup 45 /hyphen put
dup 46 /period put
dup 47 /slash put
dup 48 /zero put
dup 49 /one put
dup 50 /two put
dup 51 /three put
dup 52 /four put
dup 53 /five put
dup 54 /six put
dup 55 /seven put
dup 56 /eight put
dup 57 /nine put
dup 58 /colon put
dup 59 /semicolon put
dup 60 /less put
dup 61 /equal put
dup 62 /greater put
dup 63 /question put
dup 64 /at put
dup 65 /A put
dup 66 /B put
dup 67 /C put
dup 68 /D put
dup 69 /E put
dup 70 /F put
dup 71 /G put
dup 72 /H put
dup 73 /I put
dup 74 /J put
dup 75 /K put
dup 76 /L put
dup 77 /M put
dup 78 /N put
dup 79 /O put
dup 80 /P put
dup 81 /Q put
dup 82 /R put
dup 83 /S put
dup 84 /T put
dup 85 /U put
dup 86 /V put
dup 87 /W put
dup 88 /X put
dup 89 /Y put
dup 90 /Z put
dup 91 /bracketleft put
dup 92 /backslash put
dup 93 /bracketright put
dup 94 /asciicircum put
dup 95 /underscore put
dup 96 /quoteleft put
dup 97 /a put
dup 98 /b put
dup 99 /c put
dup 100 /d put
dup 101 /e put
dup 102 /f put
dup 103 /g put
dup 104 /h put
dup 105 /i put
dup 106 /j put
dup 107 /k put
dup 108 /l put
dup 109 /m put
dup 110 /n put
dup 111 /o put
dup 112 /p put
dup 113 /q put
dup 114 /r put
dup 115 /s put
dup 116 /t put
dup 117 /u put
dup 118 /v put
dup 119 /w put
dup 120 /x put
dup 121 /y put
dup 122 /z put
dup 123 /braceleft put
dup 124 /bar put
dup 125 /braceright put
dup 126 /asciitilde put
dup 127 /Euro put
readonly def
currentdict end
currentfile eexec
M#1H5 J6o\&rtS(#v\0\V7Fe༙OYx5-cY9^%Y6
(efIOldN"wȰ;)UƽoFg/rvV$JS8_oc@
o9-eGJp}[Do]mN=4*{ܯq=eU^t6¤.vA2*Sr 2@Y0}Rcx,TX|ZP
;o<[1?
T<=qo:-62/]8~i wX?wJ`lLkI@EjYׅq5ڧHtvc6i 0M]YUN;M]ť0]z[{s1uO[6be#9k~d/YpMA.=뤎P\|W#?W$iz81ZL
Ңri^?WP]X A.@
z[
75y6k .U*3}hA\t&HW!Q
=+Г A 5